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ABSTRACT
Hexitol nucleic acids (HNAs) are nuclease resistant
and provide strong hybridization to RNA. However,
there is relatively little information on the biological
properties of HNA antisense oligonucleotides. In this
study, we compared the antisense effects of a chi-
meric HNA ‘gapmer’ oligonucleotide comprising a
phosphorothioate central sequence flanked by 50
and 30 HNA sequences to conventional phosphor-
othioate oligonucleotides and to a 20-O-methoxyethyl
(20-O-ME) phosphorothioate ‘gapmer’. The antisense
oligomers each targeted a sequence bracketing the
start codon of the message of MDR1, a gene involved
inmulti-drugresistance incancercells.Antisenseand
control oligonucleotides were delivered to MDR1-
expressing cells using transfection with the cationic
lipid Lipofectamine 2000. The anti-MDR1 HNA gapmer
was substantially more potent than a phosphorothio-
ate oligonucleotide of the same sequence in reducing
expression of P-glycoprotein, the MDR1 gene pro-
duct. HNA and 20-O-ME gapmers displayed similar
potency, but a pure HNA antisense oligonucleotide
(lacking the phosphorothioate ‘gap’) was ineffective,
indicating that RNase H activity was likely required.
Treatment with anti-MDR1 HNA gapmer resulted in
increased cellular accumulation of the drug surrogate
Rhodamine 123 that correlated well with the reduced
cell surface expression of P-glycoprotein. Thus, HNA
gapmers may provide a valuable additional tool
for antisense-based investigations and therapeutic
approaches.
INTRODUCTION
The development of resistance to chemotherapeutic agents is a
major obstacle in the treatment of cancer. P-glycoprotein, the
product of MDR1 gene, is a transmembrane ATP-dependent
drug efflux pump that belongs to ABC transporter family.
P-glycoprotein is found in many types of cancer cells (1–4)
as well as in normal tissues including liver, kidney, intestine,
placenta and the blood brain barrier (5,6). Expression of
MDR1 has been correlated with the increased drug resistance
and decreased clinical response in human cancers (7–9).
P-glycoprotein over-expression is also believed to be closely
related to the development of cancer cells, and inhibition of the
protein has been shown to inhibit the growth of various car-
cinomas (10,11). However, most small-molecule inhibitors of
P-glycoprotein suffer from high toxicity, complicated drug–
drug interactions and metabolic interference, most notably
through P-450 enzymes (12,13).
Nucleic-acid-based drug design has provided therapeutic
agents such as antisense oligonucleotides, hammerhead ribo-
zymes and siRNA that provide an alternative to small mole-
cule drugs. These oligonucleotides all act at the mRNA level in
a sequence-specific manner (14). Antisense oligonucleotides
usually work either by translation arrest or by target degrada-
tion through RNase H activation (15–20). Extensive modifica-
tions of antisense oligonucleotides have been developed to
overcome the intrinsic instability of normal phosphodiester
oligonucleotides in a cellular environment (21–26). However,
most first- and second-generation modified antisense oligonu-
cleotides suffer from undesirable effects due to non-specific
binding to certain cell proteins (27), lack of RNase H activation
(28,29), or poor cellular uptake (29). A chimeric or ‘gapmer’
approach has been employed to overcome these obstacles by
combining stable modified residues at 50 and 30 positions with
phosphodiester or phosphorothioate residues in a central seg-
ment; this has proved to be a worthwhile approach (30–35).
The ribozyme approach has also encountered similar pro-
blems, and is in the process of optimization for therapeutic
purposes (36). SiRNA is thought to work as an RNA–protein
complex known as RNA-induced silencing complex, and its
activity on target gene regulation has been widely demon-
strated (37–41). Concerns about in vivo therapeutic application
of siRNA include actions on non-targeted genes (42–44) and
activation of the innate immune response (45). MDR1 gene
expression has been successfully modulated by antisense
oligonucleotides (34,35,46–51), hammerhead ribozymes
(52–56) and siRNA (57,58).
Hexitol nucleic acids (HNAs; Figure 1) are oligonucleotide
derivatives with a six-membered carbohydrate moiety that
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display strong hybridization affinity and resistance to nucleases
(59). In solution, HNA–RNA hybrids form an A-type anti-
parallel heteroduplex similar to dsRNA (60). Antisense effects
of HNA oligonucleotides have been evaluated for mutated
Ha-ras mRNA in a rabbit reticulocyte extract and for intracel-
lular adhesion molecule-1 expression in a mammalian cell sys-
tem (61). Also, the carbamoyl phosphate synthatase II gene of
the human malaria parasite Plasmodium falciparum has been
targeted (62). In the cellular study, HNAs were less effective
than phosphorothioates; this was attributed to the lack of RNase
H activation mechanism and low cellular uptake (59,61). How-
ever, this study did not make use of HNA gapmers capable of
supporting RNaseH activity in the cell-based experiments.
In the current study, chimeric HNA-phosphorothioate
‘gapmers’ targeting the AUG start codon of MDR1 gene
were prepared and complexed with Lipofectamine 2000 for
cellular delivery. The antisense effects of the HNA derivatives
on multi-drug resistant (MDR) NIH 3T3 MDR cells and NCI/
ADR-RES cells were compared to those of a pure phosphor-
othioate counterpart, as well as to a chimeric 20-O-




The HNA phosphoramidite building blocks were synthesized
as described previously (63). The HNA and chimeric
HNA-phosphorothioate derivatives were synthesized using
the phophoramidites according to a previously reported pro-
cedure (64). Unmodified phosphorothioate oligonucleotide
was purchased from Midland Certified Reagent Company
(Midland, TX). Chimeric 20-O-ME phosphorothioate derivat-
ives were synthesized at ISIS Pharmaceticals using previ-
ously described procedures (65). Oligonucleotide sequences
either targeting the AUG start codon of the MDR1 gene or
scrambled/mismatched sequences are summarized in Table 1.
All the oligonucleotides used in this study were purified by
high-performance liquid chromatography (HPLC). Mass
spectra were acquired for HNA derivatives on a
quadrupole/orthogonal-acceleration time-of-flight tandem
mass spectrometer equipped with a standard electrospray
ionization interface: HNA antisense (GS1954) [calculated,
6350.3 mass units; found, 6350.7 mass units]; HNA mismatch
(GS1955) [calculated, 6366.4 mass units; found, 6366.7 mass
units]; HNA gapmer (GS1956) [calculated, 6366.0 mass units;
found, 6366.7 mass units]; HNA gapmer mismatch (GS1957)
[calculated, 6382.1 mass units; found, 6382.8 mass units].
Cells
NIH 3T3 cells stably transfected with a plasmid containing the
human MDR1 gene (pSKI MDR) were a gift from
M. M. Gottesman (66). The NIH 3T3 cells expressing the
human MDR1 gene (NIH 3T3 MDR cells) were grown in
Dulbecco’s Modified Eagle’s Medium (DMEM) containing
10% fetal bovine serum (FBS) and 60 ng/ml of colchicine
in a humidified atmosphere of 95% air and 5% CO2 at
37C. MDR NCI/ADR-RES breast carcinoma cells were
grown in minimum essential medium (MEM) containing
10% FBS under the same conditions. These cells have attained
their MDR status via chronic exposure to doxorubicin.
Oligonucleotide treatment
Lipofectamine 2000 (Invitrogen, 2 mg/ml) complexes of an
oligonucleotide in Opti-MEM were freshly prepared accord-
ing to the manufacturer’s recommendations. DMEM and
MEM media were used for NIH 3T3 MDR cells and NCI/
ADR-RES cells, respectively, throughout the experiments.
The cells were seeded onto six-well plates in aliquots of
3 · 105 per well in the corresponding medium containing
10% FBS. After 24 h, cells were treated with the oligonucleo-
tide Lipofectamine 2000 complex (2 mg/ml) in the correspond-
ing fresh medium (2 ml) containing 10% FBS for 4 h at 37C.
The cells were then washed twice with 10% FBS/DMEM or
10% FBS/MEM and incubated in the corresponding medium
at 37C. After 1 h, cells were either washed again for oligo-
nucleotide uptake analysis or plated on fibronectin-coated
coverslips for confocal fluorescence microscopy analysis.
For studies of cytotoxicity, expressed P-glycoprotein levels
through immunostaining (by flow cytometry and western blot-
ting) and Rhodamine 123 accumulation (by flow cytometry),
Figure 1. Chemical structures of oligonucleotides employed in this study as compared to phosphodiester oligonucleotides.
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cells were further incubated in the corresponding medium
containing 2% FBS for 64 h.
Oligonucleotide uptake by cells
NIH 3T3 MDR cells were treated with fluorescently labeled
HNA or HNA gapmer derivatives (1, 3, 9 and 27 nM) com-
plexed with Lipofectamine 2000 (2 mg/ml) for 4 h in 10% FBS/
DMEM. The cells were washed twice with 10% FBS/DMEM
and incubated for 1 h in 10% FBS/DMEM. The cells were
then washed with phosphate-buffered saline (PBS), detached
and centrifuged at 1100 r.p.m. for 5 min. PBS was added to
the sedimented cells for fluorescence uptake analysis using
flow cytometry.
Western blotting for P-glycoprotein expression
After treating with an oligonucleotide as described above,
and further incubation for 64 h, NIH 3T3 MDR cells were
detached, counted for normalization and harvested for western
analysis. The cells were lysed in a modified radioimmunopre-
cipitation buffer (150 mM NaCl, 50 mM Tris pH 7.4, 1%
NP40, 0.5 mM deoxycholate, 5 mM EDTA, 1 mM dithiothrei-
tol, 2 mM phenylmethylsulfonyl fluoride, 0.1% aprotinin and
0.1% SDS), and lysates were microfuged at 12 000 r.p.m. for
10 min at 4C. Equal amounts of protein (20 mg) were mixed
with 4· SDS sample buffer and were boiled for 5 min. The
proteins were electrophoresed on a 7% SDS–polyacrylamide
gel and the separated proteins were transferred onto polyvinyl-
idene difluoride membranes (Millipore, Bedford, MA). The
MDR1 expression was detected using monoclonal anti-P-
glycoprotein C219 antibody (Signet Laboratory, Dedham,
MA) at 2 mg/ml in 1% BSA. Peroxidase-conjugated rat
anti-mouse immunoglobulin G (IgG) antibody (Calbiochem,
San Diego, CA) at a dilution of 1:3000 was used as a secondary
antibody in 3% BSA/1% Tween-20. Actin was detected by
anti-actin primary antibody (Sigma-Aldrich) at a dilution of
1:6000. Signals were detected by enhanced chemilumines-
cence (ECL kit, Amersham Biosciences, Piscataway, NJ).
Confocal microscopy
Cellular uptake and subcellular distribution of HNA oligonu-
cleotide derivatives were investigated by confocal fluores-
cence microscopy. NIH 3T3 MDR cells were treated with
fluorescently labeled HNA derivative (10 nM) complexed
with Lipofectamine 2000 (2 mg/ml) for 4 h in 10% FBS/
DMEM. The cells were washed twice with 10%
FBS/DMEM and incubated for 1 h in 10% FBS/DMEM.
The cells were then plated on fibronectin (10 mg/ml) coated
glass coverslips for 2 h in complete media at 37C. The adher-
ent cells were fixed in 4% formaldehyde for 10 min, rinsed
twice with PBS, rinsed once with distilled water and then
mounted onto glass slides with PermaFluor mounting medium
(Shandon Immunon, Pittsburgh, PA). Images were taken using
an Olympus confocal microscope with a 60· objective lens
and processed using Fluoview software.
Cytotoxicity
NIH 3T3 MDR cells were treated with Lipofectamine 2000
complexes of oligonucleotides, washed and further incubated
for 64 h as described above. The cells were then detached,
washed twice with PBS and counted using an Elzone particle
cell counter (Micromeritics, Norcross, GA) to measure the
number of surviving cells. Longer-term studies of cytotoxicity
were performed by assaying cell growth in complete medium
over a period of five days after oligonucleotide treatment.
Immunostaining of P-glycoprotein
The P-glycoprotein expression on viable cell membrane sur-
faces was studied by immunostaining using a flow cytometry
assay. After treating NIH 3T3 MDR cells or NCI/ADR-RES
cells with oligonucleotide and further incubating them for 64 h,
as described above, the cells were trypsinized, washed twice
with PBS, counted for normalization and incubated with
MRK16 (Kamiya, Seattle, WA) anti-P-glycoprotein primary
antibody in PBS (20 mg/ml, 45 min) at 4C. The cells were
then washed with PBS three times, and treated with an anti-
mouse IgG secondary antibody conjugated with R-phycoery-
thrin (Sigma, St Louis, MO) for 30 min in 10% FBS/PBS at
4C and then washed with 10% FBS/PBS three times. The
levels of immunostaining by R-phycoerythrin in viable cells
(identified by light scattering) were then quantified on a
Becton Dickinson flow cytometer using Cicero software
(Cytomation, Fort Collins, CO).
Rhodamine 123 accumulation
The fluorophore Rhodamine 123 is a substrate for the P-
glycoprotein efflux pump. Thus, the Rhodamine 123 accumu-
lation is often used as a surrogate for drug uptake. NIH 3T3
MDR cells were treated with oligonucleotides complexed with
Lipofectamine 2000 as described above. After 64 h, the cells
were trypsinized and suspended in DMEM/10% FBS. The
Table 1. Oligonucleotides targeted to the MDR1 gene and scrambled/mismatched controls
Name Target Sequence Chemical property
5995 AUG start codon of MDR1 50-CCA TCC CGA CCT CGC GCT CC-30 PS
10 221 Scrambled control of 5995 50-CAC CAC CCC CCT CGC TGG TC-30 PS
13 758 AUG start codon of MDR1 50-CCA TCC CGA CCT CGC GCT CC-30 PS, 20-O-ME and PS
13 753 Scrambled control of 13 758 50-CAC CAC CCC CCT CGC TGG TC-30 PS, 20-O-ME and PS
GS1954 AUG start codon of MDR1 60-CCA TCC CGA CCT CGC GCT CC-propanediol-40 HNA
GS1955 Mismatched control of GS1954 60-CCA TAC CAA CAT CAC GCT CC-propanediol-40 HNA
GS1956 AUG start codon of MDR1 60-CCA TCC CGA CCT CGC GCT CC-propanediol-40 PS, HNA
GS1957 Mismatched control of GS1956 60-CCA TAC CAA CAT CAC GCT CC-propanediol-40 PS, HNA
GS1962 AUG start codon of MDR1 60-fl-CCA TCC CGA CCT CGC GCT CC-propanediol-40 HNA
GS1964 AUG start codon of MDR1 60-fl-CCA TCC CGA CCT CGC GCT CC-propanediol-40 PS, HNA
PS, phosphorothioate internucleotide linkage; 20-O-ME, 20-O-methoxyethylribonucleoside; HNA, HNA with phosphodiester internucleotide linkage; fl: fluorescein.
Non-italic, phosphodiester; italic, phosphorothioate; bold, 2’-O-ME; underline, HNA.
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cells were washed once and resuspended in complete medium
and warmed to 37C before adding Rhodamine 123 (1 mg/ml).
After 1 h at 37C, cells were washed once with cold PBS and
resuspended in PBS. The accumulation of Rhodamine 123
inside viable cells was measured by flow cytometery as
described (35).
RESULTS
Description of the antisense oligonucleotides
studied
Oligonucleotides prepared for this study are summarized in
Table 1. Antisense activity against MDR1 has been previously
described for the phosphorothioate oligonucleotides 5995 and
10 221, and for the chimeric 20-O-ME phosphorothioate oli-
gonucleotides 13 758 and 13 753 (34,35). Phosphorothioate
oligonucleotide 5995, chimeric (gapmer) 20-O-ME phosphor-
othioate oligonucleotide 13 758, HNA oligonucleotide GS
1954 and chimeric (gapmer) HNA phosphorothioate oligonu-
cleotide GS1956 are directed to the AUG start codon region
(positions 409–428) of MDR1 message, while phosphorothio-
ate oligonucleotide 10 221, chimeric (gapmer) 20-O-ME phos-
phorothioate oligonucleotide 13 753, HNA oligonucleotide
GS1955 and chimeric (gapmer) HNA phosphorothioate oligo-
nucleotide GS1957 are their scrambled and mismatched con-
trols, respectively. HNA GS1962 and chimeric (gapmer) HNA
phosphorothioate oligonucleotide GS1964 are fluorescently
labeled sequences of GS1954 and GS1956, respectively.
Cellular uptake and subcellular distribution of HNA
derivatives
Lipofectamine 2000 (2 mg/ml) complexes of either fluores-
cently labeled HNA (GS1962, 10 nM) or fluorescently labeled
chimeric HNA phosphorothioate derivative (HNA gapmer,
GS1964, 10 nM) were transfected into NIH 3T3 MDR cells
for cellular uptake and distribution analyses. Confocal micro-
scopy indicated that fluorescence was mostly in cell nuclei
(Figure 2), suggesting that both HNA and HNA gapmer were
taken by NIH 3T3 MDR cells and eventually redistributed to
nuclei. A fraction of the cell population was not transfected as
indicated by cells lacking any fluorescence (Figure 2B, panel c).
Cytotoxicity of oligonucleotide complexes
The concentration dependence of the cytotoxicities of HNA
(GS1954), HNA gapmer (GS1956), phosphorothioate (5995)
and 20-O-ME gapmer oligonucleotides (13 758) were evalu-
ated under the same conditions as those used for testing anti-
sense effects. All four types of antisense derivatives were
relatively non-toxic up to 10 nM with cell survival being
>80% of control; however, HNA (GS1954) and HNA phos-
phorothioate gapmer (GS1956) reduced cell survival to 53 and
36% of control, respectively, at 27 nM, while phosphorothio-
ate (5995) and chimeric 20-O-ME gapmer (13 758) reduced
cell survival to 72 and 69% of control, respectively (Figure 3).
Thus, the HNA oligomers were non-toxic at low concentra-
tions but were more toxic than phosphorothioate or 20-O-ME
gapmer when used at higher concentrations. Cells were also
assayed for growth in complete medium over a period of five
days after treatment. No differences were observed between
Figure 2. Cellular uptake and distribution of HNA derivatives. NIH 3T3 MDR
cells were treated with fluorescein-labeled HNA derivatives (10 nM)
complexed with Lipofectamine 2000. (A) HNA (GS1954); (B) HNA
gapmer (GS1956). (a) fluor-labeled oligonucleotide; (b) phase contrast
image; (c) overlay image. Note that some of the cells lack fluorophore (arrow).
Figure 3. Cytotoxicity of oligonucleotides. The cytotoxicities of antisense
oligonucleotides were determined after treatment of NIH 3T3 MDR cells
with various concentrations of antisense/Lipofectamine 2000 complexes and
further incubating them for 64 h as described. Closed circles, control cells
treated with Lipofectamine 2000 only; closed squares, HNA (GS1954);
closed triangles, HNA gapmer (GS1956); open squares, phosphorothioate
(5995); open triangles, 20-O-ME gapmer (13 158). Values represent cell
population in percentage with 100% taken for untreated NIH 3T3 MDR
cells. Means and standard errors of 3–6 determinations.
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cells treated with Lipofectamine 2000 alone or with Lipofect-
amine 2000 plus HNA gapmer at 9 nM (data not shown).
Thus, at lower concentrations the HNA gapmer is only min-
imally toxic.
Cellular uptake of oligonucleotides
Fluorophore-labeled HNA and HNA gapmer exhibited similar
uptake by NIH 3T3 MDR cells. Figure 4 shows uptake of the
HNA gapmer. While the percentage of fluorescent cells in-
creased linearly (up to 54% at 27 nM of HNA gapmer), the rela-
tive fluorescence strengths increased more sharply at higher
oligonucleotide concentration (5.2 at 3 nM, 14.8 at 9 nM and
43.2 at 27 nM). The results imply that the amount of oligo-
nucleotide per transfected cell is much greater at higher oligo-
nucleotide concentration. This uptake result correlates with
antisense effects on P-glycoprotein inhibition as well as the
observed cytotoxicity at higher oligonucleotide concentrations.
Inhibition of P-glycoprotein expression measured by
flow cytometry
Antisense effects of HNA (GS1954), HNA gapmer (GS1956),
phosphorothioate (5995) and 20-O-ME gapmer (13 758) deri-
vatives on cell surface P-glycoprotein expression in viable
NIH 3T3 MDR cells or NCI/ADR-RES cells were evaluated
Figure 4. Oligonucleotide uptake by cells. NIH 3T3 MDR cells were treated with Lipofectamine 2000 complexes of fluorescein labeled HNA gapmer as described.
The fluorescence of the cells was then measured by flow cytometry. (A) x-Axes represent fluorescence intensities and y-axes represent the cell number. (a) Untreated
negative control cells; (b) 1 nM HNA gapmer; (c) 3 nM HNA gapmer; (d) 9 nM HNA gapmer; (e) 27 nM HNA gapmer. (B) x-Axis represents HNA gapmer
concentrations, y-axis at left and open bars represent the percentage of the cell population that is transfected; y-axis at right and closed circles represent relative
fluorescence strengths. Means and standard errors of three determinations.
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using immunofluorescence and flow cytometry. The control
oligonucleotides 10 221, 13 753, GS1955 and GS1957 were
also tested. The cells were treated with oligonucleotide com-
plexed to Lipofectamine 2000 as described above. Figure 5
compares P-glycoprotein reductions in NIH 3T3 MDR cells
caused by HNA gapmer, phosphorothioate and 20-O-ME
gapmer at 9 nM, while Figure 6 shows the effects on NCI/
ADR-RES cells. As seen in both cell types, the HNA gapmer
Figure 5. Antisense effects on P-glycoprotein expression in NIH 3T3 MDR cells. NIH 3T3 MDR cells were treated with Lipofectamine 2000 complexes of various
oligonucleotides, and cell surface P-glycoprotein expression in the viable cells was evaluated as described in Materials and Methods. x-Axes represent fluorescence
intensity and y-axes represent cell number. Panels (A, D and G), control (Lipofectamine 2000 only); (B) 9 nM HNA gapmer mismatched (GS1957); (C) 9 nM HNA
gapmer (GS1956); (E) 9 nM phosphorothioate scrambled control (10 221); (F) 9 nM phosphorothioate (5995); (H) 9 nM 20-O-ME gapmer scrambled (13 753)
(I) 9 nM 20-O-ME gapmer (13 758). The demarcations between the left and right boxes in the figures are set at one standard deviation below the mean of the
untreated control.
Figure 6. Antisense effects on P-glycoprotein expression in NCI/ADR-RES cells. NCI/ADR-RES cells were treated with Lipofectamine 2000 complexes of various
oligonucleotides, and cell surface P-glycoprotein expression in the viable cells was evaluated as described in Materials and Methods. x-Axes represent fluorescence
intensity and y-axes represent cell population. Panels (A, D and G), controls (Lipofectamine 2000 only); (B) 9 nM HNA gapmer mismatched (GS1957); (C) 9 nM
HNA gapmer (GS1956); (E) 9 nM phosphorothioate scrambled control (10 221); (F) 9 nM phosphorothioate (5995); (H) 9 nM 20-O-ME gapmer scrambled (13 753)
(I) 9 nM 20-O-ME gapmer (13 758). The demarcations between the left and right boxes in the figures are set at one standard deviation below the mean of the
untreated control.
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was substantially more effective than the phosphorothioate
and was comparable to the 20-O-ME gapmer derivative.
Antisense effects could not be measured quantitatively at
higher concentrations due to cytotoxicity (data not shown).
Antisense effects on P-glycoprotein expression were concen-
tration dependent (Figure 7). The HNA gapmer (GS1956) and
20-O-ME gapmer (13 758) displayed a similar concentration–
response profile, while over the concentration range tested, the
phosphorothioate (5995) was less effective.
Selective reduction of P-glycoprotein measured by
western blot
The MDR1 gene expression in response to antisense and con-
trol oligonucleotides was evaluated by western blotting
(Figure 8). At a concentration of 10 nM, the HNA gapmer
(GS1956) and 20-O-ME gapmer significantly reduced the
P-glycoprotein expression, while the antisense phosphorothio-
ate (5995) and the control oligonucleotides were less or not
effective. Expression of actin was not affected by any of the
oligomers.
Accumulation of Rhodamine 123
Accumulation of fluorescent Rhodamine 123 by NIH 3T3 MDR
cells was measured by flow cytometry after exposure to 9 nM
oligonucleotide. Both the HNA (GS1956) and 20-O-ME
(13 758) gapmers enhanced Rhodamine 123 accumulation
by 200%, while the control sequences GS1957 and 13 753
did not (Figure 9). Unmodified phosphorothioate (5995)
slightly enhanced cellular accumulation of the drug, while
the fully HNA oligonucleotide, GS1954, exhibited minimal
effects.
DISCUSSION
Selective inhibition of the P-glycoprotein efflux pump in MDR
cancer cells is potentially an important objective in anti-cancer
chemotherapeutics. This research demonstrates effective
inhibition of MDR1 gene expression by a novel class of
HNA antisense oligonucleotide derivatives. Both unmodified
HNA and its phosphorothioate chimeric (gapmer) derivative
were prepared; these targeted a sequence bracketing the AUG
start codon of MDR1. The HNA oligonucleotides were com-
pared to unmodified phosphorothioate and 20-O-ME gapmer
oligonucleotides with the same sequence.
Complexation with the cationic lipid Lipofectamine 2000
provided delivery of fluorophore-tagged HNA oligonucleo-
tides to NIH 3T3 MDR cells, as evidenced by concentration
of the fluorophore in the nucleus; however, some cells
remained untransfected. HNA oligonucleotides were not
toxic when used at low concentrations, but seemed to be some-
what more toxic to cells than the phosphorothioate or 20-O-ME
gapmer oligonucleotides when used at higher concentrations.
The increased toxicity of HNA derivatives may be due to their
stability and resistance to degradation (60–65).
Figure 8. Western blots for P-glycoprotein expression. After treating NIH 3T3
MDR cells with various antisense/Lipofectamine 2000 complexes as described,
cells were harvested for western analysis. Lane 1, Lipofectamine 2000 only
control; lane 2, HNA gapmer (GS1956); lane 3, phosphorothioate (5995); lane
4, 20-O-ME gapmer (13 758); lane 5, HNA gapmer mismatch (GS1957); lane 6,
phosphorothioate scrambled (10 221); lane 7, 20-O-ME gapmer scrambled
(13 753). All oligonucleotides were used at a 10 nM concentration.
Figure 9. Effects of antisense oligonucleotides on Rhodamine 123
accumulation. NIH 3T3 MDR cells were treated with 9 nM of antisense
oligonucleotides complexed with Lipofectamine 2000 as described. Closed
bars, control oligonucleotides; open bars, oligonucleotides targeted to
MDR1 gene. Values are Rhodamine 123 uptake increase, with the 100%
level taken as that for untreated NIH3T3 MDR cells. Mean and standard
errors of 3–6 determinations.
Figure 7. Antisense concentration dependence of P-glycoprotein expression.
Cell surface P-glycoprotein expression in NIH 3T3 MDR cells was measured by
immunostaining and flow cytometry as described in Materials and Methods.
Closed circles, control cells treated with Lipofectamine 2000 only; closed
squares, HNA (GS1954); closed triangles, HNA gapmer (GS1956); open
squares, phosphorothioate (5995); open triangles, 20-O-ME gapmer (13 158).
Values are percentage of P-glycoprotein expression with 100% taken for NIH
3T3 MDR cells treated with corresponding mismatched or scrambled sequence.
The percentage was calculated on the basis of the fraction of the cell population
shifted to greater than one standard deviation below the mean of the untreated
controls in terms of P-glycoprotein expression. Means and standard errors of
3–6 determinations.
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The inhibition of MDR1 gene expression was assayed by
examining levels of P-glycoprotein, the MDR1 gene product.
The HNA gapmer proved to be extremely potent in these
assays, displaying 50% inhibition of P-glycoprotein expres-
sion when used at 10 nM. This was equivalent to the potency
of the 20-O-ME gapmer which had provided by far the most
effective inhibition of P-glycoprotein expression observed
previously (34,35). The unmodified HNA oligomer was not
effective in inhibiting P-glycoprotein expression, suggesting
that RNase H activity is essential for this to occur. Reduced
P-glycoprotein expression was reflected in a parallel increase
in drug accumulation in the NIH 3T3 MDR cells, as evaluated
using a flow cytometry assay for Rhodamine 123 accumula-
tion. In these studies, we did not attempt to measure changes in
resistance to anti-tumor drugs, since a fraction of the cell
population did not take up the antisense oligonucleotides,
and thus would be expected to remain resistant.
In summary, this research has demonstrated that chimeric
HNA phosphorothioate oligonucleotide gapmers can effect-
ively inhibit MDR1 gene expression. The great potency of
the HNA gapmer allows its use at non-toxic concentrations.
Further, although the HNA gapmer displayed some toxicity at
higher concentrations, this might be attenuated by use of phos-
phodiester internucleotide linkages, rather than phosphor-
othioate, in the ‘gap’ segment. This approach may reduce
the observed cytotoxicity while maintaining the required
nuclease resistance and target binding, thus enhancing the
desired gene regulation capabilities. It would seem worthwhile
to pursue this approach in future studies, as well as seek more
efficient methods for delivery of HNAs and other antisense
oligonucleotides.
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